You are here: Home: Audio Program Guide: CCU 5 | 2006 Audio
 
  Go to interview with Axel Grothey, MD
Go to interview with Daniel G Haller, MD
Go to interview with Charles S Fuchs, MD, MPH
Go to interview with Neal J Meropol, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Axel Grothey, MD
Senior Associate Consultant
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 OPTIMOX2: Maintenance therapy or chemotherapy-free intervals after FOLFOX
Track 3 Clinical trial incorporating a maintenance or chemotherapy-free interval strategy with bevacizumab
Track 4 Selection of FOLFOX or FOLFIRI with bevacizumab as first-line therapy
Track 5 Therapeutic approach with curative intent for patients with metastatic disease
Track 6 Treatment of patients with synchronous primary and metastatic disease
Track 7 Clinical management of potentially resectable hepatic-only metastases
Track 8 NSABP-C-09: CAPOX with or without hepatic arterial infusion of floxuridine for resected or ablated liver metastases
Track 9 Ongoing adjuvant clinical trials evaluating FOLFOX with biologic therapy
Track 10 Tolerability and side effects of biologic therapies in the adjuvant setting
Track 11 Potential rationale for efficacy of adjuvant bevacizumab
Track 12 Selection of adjuvant chemotherapeutic regimens
Track 13 Use of adjuvant fluoropyrimidine monotherapy
Track 14 NSABP-R-04: Preoperative radiation therapy and oral versus intravenous 5-FU with or without oxaliplatin for rectal cancer
Track 15 Use of postoperative adjuvant therapy for rectal cancer
     
Daniel G Haller, MD
Professor of Medicine
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 US BRiTE registry trial: Side effects and toxicity of bevacizumab in clinical practice
Track 3 Predicting risk of bevacizumab-associated arterial thrombotic events
Track 4 Acquired hypertension as a predictor of response to bevacizumab
Track 5 Cetuximab-associated rash: Implications for adjuvant therapy
Track 6 Preoperative versus postoperative chemoradiation therapy for rectal cancer
Track 7 The importance of downstaging rectal cancer
Track 8 Rationale for incorporating oxaliplatin with preoperative radiation therapy for rectal cancer
Track 9 Selection of oral versus infusional fluoropyrimidine therapy
Track 10 Geographic variability in the tolerability of fluoropyrimidines
Track 11 Use of preoperative response to chemoradiation therapy to determine postoperative adjuvant therapy for rectal cancer
     
Charles S Fuchs, MD, MPH
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard University
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Use of irinotecan-containing regimens in the adjuvant setting
Track 3 Effects of physical activity on patients with colon cancer
Track 4 Influence of regular aspirin use on survival for patients with colon cancer
Track 5 Potential mechanisms of aspirin, diet and exercise on risk of cancer recurrence
Track 6 Feasibility of prospectively evaluating aspirin, diet or exercise in clinical trials
Track 7 Counseling patients about dietary and lifestyle modifications
Track 8 Selection of adjuvant chemotherapy for patients with Stage II disease
Track 9 Ongoing adjuvant clinical trials incorporating biologic therapies
Track 10 Studies evaluating chemotherapy in combination with biologic doublets in the metastatic setting
Track 11 Approach to patients with synchronous primary and metastatic colon cancer
Track 12 Selection of first-line chemotherapy
Track 13 OPTIMOX2: Maintenance therapy or chemotherapy-free intervals after FOLFOX for patients with metastatic disease
     
Neal J Meropol, MD
Director, Gastrointestinal Cancer Program
Director, Gastrointestinal Tumor Risk Assessment Program
Divisions of Medical Science and Population Science
Fox Chase Cancer Center
Philadelphia, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 OPTIMOX2: Maintenance therapy versus chemotherapy-free intervals
Track 3 Selection of patients with metastatic disease for an intermittent chemotherapeutic strategy
Track 4 Determination of bevacizumab dose in combination with chemotherapy
Track 5 Societal and economic impact of the cost of cancer therapies
Track 6 Predictors of response to EGFR and VEGF inhibitors
Track 7 Key clinical research questions regarding the use of biologic therapies
Track 8 Use of cetuximab/bevacizumab combination antibody therapy
Track 9 Clinical trials evaluating curative intent strategies for patients with initially unresectable metastatic disease
Track 10 Geographic differences in the tolerability of capecitabine
Track 11 Intensive surveillance for early identification of metastatic disease after adjuvant therapy
Track 12 Changing patterns of metastases in colorectal cancer
Track 13 Selection of adjuvant therapy for elderly patients
Track 14 Selection of an oral versus intravenous fluoropyrimidine as monotherapy